Company: Aptinyx, Inc.
Symbol: APTX
Description: They are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.
Trade Date: 6/21
Shares: 5.33 million
Price Range: $14.00-$16.00
Underwriter(s): J.P. Morgan, Cowen, Leerink Partners, BMO Capital Markets
Terms Added: 6-11-18
Business: They are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. They focus their efforts on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system. They believe leveraging the therapeutic advantages of the differentiated modulatory mechanism of their compounds will drive a paradigm shift in the treatment of disorders of the brain and nervous system.
They are currently studying their first product candidate, NYX-2925, in two Phase 2 studies in chronic pain. The first is in subjects with painful diabetic peripheral neuropathy, or DPN, and the second is in subjects with fibromyalgia. They expect to report top-line data from these studies in the first half of 2019. Their second product candidate, NYX-783, has been evaluated in Phase 1 clinical development. They intend to develop NYX-783 for the treatment of post-traumatic stress disorder, or PTSD, and plan to initiate a Phase 2 clinical study in the second half of 2018. For their third product candidate, NYX-458, they have received written clearance to proceed with clinical investigation from the U.S. Food and Drug Administration, or FDA, and plan to initiate a Phase 1 study in the second half of 2018. They intend to develop NYX-458 for the treatment of cognitive impairment associated with Parkinson’s disease.
Insider Buying: Certain of their existing stockholders, including entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $30 million in shares of their common stock in this offering at the initial public offering price per share.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish